Sugi Predict

Sugi Predict / Compounds / SCHEMBL828268

SCHEMBL828268

SCHEMBL828268

Cc1ccnc(NC2CCOCC2)c1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.71
▸ KDM4E B2RXH2 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ PDE10A Q9Y233 1/20 0.60
▸ NOS3 P29474 1/20 0.53
▸ NOS1 P29475 1/20 0.53
▸ NOS2 P35228 1/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ LRRK2 Q5S007 1/20 0.47
▸ MAPK14 Q16539 5/20 0.46
▸ CSNK1D P48730 1/20 0.46
▸ MAPK10 P53779 5/20 0.46
▸ PDE5A O76074 1/20 0.45
▸ MAPK8 P45983 4/20 0.44
▸ MAPK9 P45984 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15830579 0.91 ALDH1A1 (0.63) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL827883 0.88 ALDH1A1 (0.83) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL13922609 0.85 KDM4E (0.97) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL15830498 0.85 ALDH1A1 (0.90) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL17303942 0.83 ALDH1A1 (0.66) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL13922608 0.83 KDM4E (1.00) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL7698244 0.81 ALDH1A1 (0.71) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL15229217 0.81 MAPK10 (0.50) ALDH1A1KDM4EL3MBTL1PDE10AMAPK1
SCHEMBL15830500 0.81 KDM4E (0.71) ALDH1A1KDM4EL3MBTL1PDE10ANOS3
SCHEMBL20449771 0.81 MAPK1 (0.53) ALDH1A1KDM4EL3MBTL1PDE10ANOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
WO-2021025407-A1 OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 웰마커바이오 주식회사 2021-02-11 — — WO disclosed
EP-3498701-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2019-06-19 — — EP disclosed
EP-2935243-B1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF EPIZYME INC (US) 2018-03-14 — — EP disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 — — US disclosed
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2017-11-02 — — US disclosed
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2017-11-02 — — US disclosed
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2017-11-02 — — US disclosed
US-9745291-B2 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. (US) 2017-08-29 — — US disclosed
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2013-02-21 — — US disclosed
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2013-02-21 — — US disclosed
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2013-02-21 — — US disclosed
US-8143294-B2 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors BURNET MICHAEL (DE) 2012-03-27 — — US disclosed
US-8143294-B2 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors BURNET MICHAEL (DE) 2012-03-27 — — US disclosed
US-8143294-B2 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors BURNET MICHAEL (DE) 2012-03-27 — — US disclosed
WO-2011100769-A2 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2011-08-18 — — WO disclosed
US-20090270462-A1 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SYNOVO GMBH (DE) 2009-10-29 — — US disclosed
US-20090270462-A1 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SYNOVO GMBH (DE) 2009-10-29 — — US disclosed
US-20090270462-A1 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SYNOVO GMBH (DE) 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER MAP3K10, MAP3K12, MAP3K20 ALDH1A1 4439/4885KDM4E 1202/4885L3MBTL1 2479/4885
US-20130045938-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER MAP3K10, MAP3K12, MAP3K20 ALDH1A1 4439/4885KDM4E 1202/4885L3MBTL1 2479/4885
US-20090270462-A1 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS IL2, IL2RA, IL1B ALDH1A1 1127/4885KDM4E 3336/4885L3MBTL1 4640/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 ALDH1A1 1890/4885KDM4E 36/4885L3MBTL1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.